Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform

Informazioni relative al progetto

MEDMICO

ID dell’accordo di sovvenzione: 666676

DOI

10.3030/666676

Progetto chiuso

Data della firma CE 2 Giugno 2015

Data di avvio 1 Luglio 2015

Data di completamento 31 Dicembre 2018

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 4 487 525,00

Contributo UE

€ 4 487 525,00

Coordinato da

RADISENS DIAGNOSTICS LIMITED
Ireland

Periodic Reporting for period 3 - MEDMICO (Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform)

Periodo di rendicontazione: 2018-01-01 al 2018-12-31

Sintesi del contesto e degli obiettivi generali del progetto

Diabetes affects 8.5% (2013) of the adult European population rising to 10.3% (2035) and is associated with co-morbid conditions such as cardiovascular and renal abnormalities. These lead to diabetic complications, ischemic heart disease, heart failure and kidney failure. Management of this growing epidemic requires a shift in care management and delivery, away from central lab testing. The majority of current diagnostic monitoring for diabetes, heart disease, kidney disease and their associated complications still involves large needles and vials of blood being transported to central laboratories for testing and long waits for results.

To address the need for instant testing of any chronic disease from a finger-prick of blood on a single blood testing device, Radisens Diagnostics proposed the MEDMICO project, to develop the worlds first PoCT platform integrating the primary blood testing families of immunoassays, turbidimetry and clinical chemistry. The European Commission have funded this project (proposal number: SEP-210218471) under the H2020 call H2020-SMEINST-2-2014, Topic: PHC-12-2014.

Under MEDMICO, HbA1c, Lipids and Kidney tests will be integrated on to a single diabetes comorbid platform for improved patient monitoring within primary care, outpatient clinics and pharmacy settings. This will improve patient outcomes and healthcare efficiencies, positioning Europe at the forefront of healthcare innovation and deliver an efficient platform to combat this diabetes epidemic.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Several deliverables have been submitted during this second period to EASME for their confidential review by industry experts. All deliverables due have been submitted. These summarise the first and second phases of the platform design, development, integration and verification of the target chronic disease panels onto the Gemini platform, with method comparison data and manufacturing process development progress.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

MEDMICO will integrate panels for diabetes, cardiovascular disease and kidney disease onto its multi-mode Gemini point of care platform, delivering central laboratory performance, room temperature storage and removing the need for over-night fasting by patients. MEDMICO plans to tackle the lack of access to clinical diagnostics to society by integrating multiple clinical diagnostic needs within one multi-mode device, offering ease of use and simplified logistics,. This addresses the lack of access by empowering decentralised healthcare settings to embrace this novel platform. MEDMICO will aim to go further by targeting the pharmacy sector, thereby opening the possibility of weekend healthcare access to society. Providing greater access to healthcare for chronic disease sufferers, with a single healthcare visit and immediate diagnostic results will positively impact society, thereby improving patient outcomes, lowering chronic risk factors and will reduce the huge burden on healthcare system resources.

MEDMICO Logo